A Novel Review on Anti-Hypertensive Drug Combination - Atenolol and Amlodipine

M. Madan Mohan Reddy¹, K. Jyothirmai², D. Mahidhar Reddy³, P. Rambabu⁴, E. Anka Rao⁵, S. Revathi⁶ and B. Dayasagar⁷

¹Eisai pharmatechnology vizag, Andhra Pradesh, India.  
²Hetero drugs, Hyderabad, Andhra Pradesh, India.  
³4.5.6.7 Narayana Pharmacy college, Nellore, Andhra Pradesh, India.

ABSTRACT
Hypertension is a key independent risk factor for cardiovascular diseases (CVD), such as heart failure, stroke, coronary heart disease (CHD), and end-stage renal disease. The Sixth Report of the Joint National Committee (JNC) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 6) recommended initiation of antihypertensive therapy using a diuretic or β-blocker for patients who have no specific indications for other drug classes (Joint National Committee 1997). Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.

Keywords: Amlodipine, Atenolol, Hypertension.

INTRODUCTION
Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.

Amlodipine
Physical Characteristics of Amlodipine
Amlodipine besylate found to exist in four solid forms: anhydrate, monohydrate, dihydrate, and amorphous. The crystal structure of the dihydrate is at both 25 and -150 °C. The crystal lattices of both the dihydrate and the stable monohydrate collapse upon removal of water molecules will melt, from which the anhydrate subsequently crystallizes. Rapid cooling of the dehydration induced melt from any of the hydrates produces the amorphous form. The kinetic solubility rank order at 37 °C in water is found to be anhydrate > monohydrate > dihydrate. The dihydrate is found to be the most stable form, and other forms undergo solvent-mediated transformation (SMT) to yield the dehydrate.

<table>
<thead>
<tr>
<th>Physical Properties</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Weight</td>
<td>567.10</td>
</tr>
<tr>
<td>Ionisation constant</td>
<td>8.6</td>
</tr>
<tr>
<td>Melting point range</td>
<td>199-202°C</td>
</tr>
<tr>
<td>Loss on drying</td>
<td>Not more than 0.5%</td>
</tr>
<tr>
<td>Heavy metals ppm</td>
<td>0.002%</td>
</tr>
<tr>
<td>Total impurity</td>
<td>Not more than 1.00%</td>
</tr>
<tr>
<td>solubility</td>
<td>Freely soluble in methanol, Slightly soluble in water and propanol.</td>
</tr>
</tbody>
</table>

Chemical Properties
Molecular formula: C₂₀H₂₅ClN₂O₂•C₅H₆O₃S
Chemical name: 3-Ethyl-5-methyl (±)-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate.
Molecular structure:
Appearance
White, crystalline powder; does not mix well with water.

Stability
Avoid reaction with oxidizing agents.

Pharmacodynamics
Amlodipine dilates peripheral arterioles and thus reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements. Amlodipine has been shown to block constriction in main coronary arteries and coronary arterioles induced by calcium, potassium, adrenaline, serotonin and thromboxane A2 analogue both in normal and in ischaemic regions. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect.

Atenolol
Chemical properties
Molecular formulae: C14H22N2O3
Chemical name: 2-4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl acetamide
Molecular structure

Physical Properties

<table>
<thead>
<tr>
<th>Solvent</th>
<th>Relative Solubility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>0.3 mg/mL</td>
</tr>
<tr>
<td>Ethanol</td>
<td>3.4 mg/mL</td>
</tr>
<tr>
<td>Dmso</td>
<td>18 mg/mL</td>
</tr>
<tr>
<td>Ether</td>
<td>Practically Insoluble</td>
</tr>
</tbody>
</table>

Pharmacodynamics
It is a Beta blocker which effectively "block" the effects of adrenaline on the body's beta receptors. This reduces the nerve impulses that travel through the heart. In consequence, the heart does not have to work as hard because it needs less blood and oxygen. In addition, such drugs "block" the impulses that can cause an arrhythmia. Competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac output. A central effect leading to reduced sympathetic outflow to the periphery.

Combination of Atenolol and Amlodipine
Used for treatment of Chronic stable angina, Hypertension.

Dosage administration oral
1. Adult
   1. Per tablet contains atenolol 25 or 50 mg and amlodipine (as besylate) 5 mg.
   2. 1 tab once daily, may increase to 2 tablets daily if needed.

2. Elderly
   1. Per tablet contains atenolol 25 mg and amlodipine (besylate) 5 mg
   2. Initiate with 1 tablet daily.

3. Renal impairment
   1. Per tablet contains atenolol 25 mg and amlodipine (besylate) 5 mg
   2. Initiate with 1 tablet daily.

Pharmacokinetics
Absorption
Amlodipine: Plasma levels peak 6-12 hr after oral admin; absolute bioavailability is estimated to be 64-90%. Atenolol: Absorption...
is rapid and consistent but incomplete; about 50% of an oral dose is absorbed in the GI tract; plasma levels peak 2-4 hr after oral admin.

**Distribution**
Amlodipine: 93% bound to plasma proteins. Atenolol: 6-16% bound to plasma proteins.

**Metabolism**
Amlodipine: About 90% converted to inactive metabolites hepatically. Atenolol: Little or no hepatic metabolism.

**Excretion**
Amlodipine: 10% of parent compound and 60% of the metabolites are removed in the urine; elimination from the plasma is biphasic with terminal half-life of about 30-50 hr. Atenolol: 50% of the oral dose is removed unchanged in the faeces; absorbed drug is removed mainly via renal elimination; half-life is about 6-7 hr.

**Drug Interactions**
Additive effect when used with catecholamine depleting drugs; monitor for hypotension and marked by bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers. ia, cold extremities. Drowsiness, chest pain & impotence rarely. Hypersensitivity reactions.

**PRECAUTIONS**
1. Excessive fall of BP may occur in elderly patients.
2. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment
3. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual.
4. Lactation.
5. Safety and efficacy have not been established in children.
6. Not to be used in untreated phaeochromocytoma.

**Degradation of Combination**
Amlodipine besylate, like all members of 1,4-dihydropyridine calcium channel blockers, is photosensitive and liable to degradation both in solution and in solid state. Light catalyses its oxidation to pyridine derivatives, such as amlox (2-(2-aminoethoxy) methyl-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxy carbonyl-6-methyl pyridine), which lack therapeutic effects. Another pharmaceutical problem is the reported incompatibility in the solid formulation between amlodipine besylate and lactose in the presence of basic excipients (magnesium stearate) and water. Atenolol is said to be photo-reactive when exposed to UVA-UVB radiation with photo degradation increasing with a decrease in the pH value. The main photo degradation product at pH 7.4 was identified as 2-(4-hydroxyphenyl) acetamide.

**Overdosage**
Over dosage may cause hypotension and less commonly, congestive cardiac failure. Unabsorbed drug may be removed by gastric lavage or use of activated charcoal. Symptomatic treatment may be administered.

**Poisoning of combination and treatment**
The common feature of Atenolol toxicity is excessive blockade of the β-receptors resulting in bradycardia and hypotension. Poisoning by Amlodipine is characterized by cardiovascular toxicity with hypotension and conduction disturbances, including sinus bradycardia and varying degrees of atrioventricular block. Poisoning by Atenolol and Amlodipine usually produces hypotension and bradycardia, which may be refractory to standard resuscitation measures. For cases of Atenolol poisoning where symptomatic bradycardia and hypotension are present, high-dose glucagon is considered the first-line antidote. For cases of Amlodipine poisoning where cardio toxicity is evident, a combination of calcium and epinephrine should be used initially.

**CONCLUSION**
The review is mainly on combined usage of atenolol and amlodipine .Its dosage administration,drug interactions,overdosage,precautions,side effects,degradation of combinationandoi poisoning which mainly reduces the hypertension.
REFERENCES


7. Atenolol. The American Society of Health-System Pharmacists


10. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008;116-117.

